Vnitr Lek 2009, 55(Suppl 1):23-28

New classification of Ph negative chronic myeloproliferative neoplasias

J. Kujíčková, M. Doubek*
Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc.

New classification of Ph negative chronic myeloproliferative neoplasias starts from the previous classification of the World Health Organization from 2001. New evidence in molecular biology and new views of histopathological evaluation were the stimuli for the current revision of classification. The review introduces current classification criteria of Ph negative myeloproliferative neoplasias.

Keywords: Ph negative chronic myeloproliferative neoplasias; classification

Received: April 20, 2009; Published: February 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kujíčková J, Doubek M. New classification of Ph negative chronic myeloproliferative neoplasias. Vnitr Lek. 2009;55(Supplementum 1):23-28.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Swerdlow SH, Campo E, Hartus NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press 2008.
    2. Adam Z, Vorlíček J, Vaníček J et al. Diagnostické a léčebné postupy u maligních chorob. Druhé, aktualizované a doplněné vydání. Praha: Grada Publishing 2004.
    3. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29. Go to original source... Go to PubMed...
    4. Kralovics R, Passamonti F, Buser AS et al. A gain-of-unction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790. Go to original source... Go to PubMed...
    5. Baxter EJ, Scott LM, Campbell PJ et al. Aquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061. Go to original source... Go to PubMed...
    6. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397. Go to original source... Go to PubMed...
    7. James C, Ugo V, Le Couédic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling cause of polycythemia vera. Nature 2005; 434: 1144-1148. Go to original source... Go to PubMed...
    8. Zhao R, Xing S, Li Z et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280: 22788-22792. Go to original source... Go to PubMed...
    9. Levine RL, Loriaux M, Huntly BJ et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377-3379. Go to original source... Go to PubMed...
    10. Remacha AF, Nomdedéu JF, Puget G et al. Occurence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2006; 91: 719-720. Go to PubMed...
    11. Szpurka H, Tiu R, Murugesan G et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006; 108: 2173-2181. Go to original source... Go to PubMed...
    12. Scott LM, Tong W, Levine RL et al. JAK2 exon 12 mutations in polycythemia vera and idiopatic erytrocytosis. N Engl J Med 2007; 356: 459-468. Go to original source... Go to PubMed...
    13. Pardanani AD, Levine RL, LaSho TL et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476. Go to original source... Go to PubMed...
    14. You W, Weisbrot IM. Chronic neutrophilic leukaemia. Report of two cases and rewiew of the literature. Am J Clin Pathol 1979; 72: 233-242. Go to original source... Go to PubMed...
    15. Marchioli R, Finazzi G, Landolfi R et al. Vascular and neoplastic risk in large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224-2232. Go to original source... Go to PubMed...
    16. Andrieux JL, Demory JL. Karyotype and molecular cytogenetic studies in polycythemia vera. Curr Hematol Rep 2005; 4: 224-229. Go to PubMed...
    17. Andréasson B, Swolin B, Kutti J et al. Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol 2002; 68: 189-193. Go to original source... Go to PubMed...
    18. Cervantes F, Dupriez B, Pereira A et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901. Go to original source... Go to PubMed...
    19. Finazzi G, Harrison C. Essential thrombocythaemia. Semin Hematol 2005; 42: 230-238. Go to original source... Go to PubMed...
    20. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004; 11: 58-64. Go to original source... Go to PubMed...
    21. Brunning RD, McKenna RW, Rossai J et al. Systemic mastocytosis. Extracutaneous manifestations. Am J Surg Pathol 1983; 7: 425-438. Go to original source... Go to PubMed...
    22. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopatic. Br J Haematol 2006; 133: 468-492. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.